⌛ Did you miss ProPicks’ 13% gains in May? Subscribe now & catch June’s top AI-picked stocks early.Unlock Stocks

Intel Harnesses Blockchain to Fight Opioid Crisis

Published 05/02/2018, 08:16 AM
Updated 05/02/2018, 08:31 AM
 Intel Harnesses Blockchain to Fight Opioid Crisis
INTC
-
MCK
-
JNJ
-
BTC/USD
-

US tech giant Intel (NASDAQ:INTC) is collaborating with several healthcare companies to explore the application of blockchain technology for drug supply chain and distribution. The move comes after cryptocurrencies were criticized for aggravating the opioid crisis as they permit anonymous transactions.

Intel wants to use the technology to find where medicines slip through the cracks of the supply chain and to flag “double doctoring,” a practice where patients buy more drugs with the same prescription.

David Houlding, director of healthcare privacy and security at Intel Health and Life Sciences, told Bloomberg:

“It will vastly reduce the opioid epidemic. I would not say this will eliminate the opioid problem, but this will help.”

The experiment is currently in progress, with pharma giant Johnson & Johnson (NYSE:JNJ) and drug wholesaler McKesson Corp (NYSE:MCK) among those entering simulated data into a blockchain. The pilot aims to track the full route of a drug – from the manufacturer to the patient.

Houlding revealed that the project might go live if it proves to be successful. Implementation can start by the end of this year.

The ultimate goal is to encourage all pharmaceutical companies and their global suppliers to move on blockchain. If that happens, US government agencies such as the Food and Drug Administration (FDA) could provide better oversight.

The opioid crisis worsened after the 2000s. Opioids include prescription painkillers like OxyContin or fentanyl and illegal drugs such as heroin. About 115 people in the US die each day from an overdose.

Blockchain technology could help trace drugs from the manufacturer to the patient’s home while allowing total privacy. Blockchain-oriented startup iSolve, which has been Intel’s partner since 2017, is developing a system called BlockRx to connect drug companies to medical device makers.

Darryl Glover, iSolve’s chief clinical officer, said:

“We’d be able to say, ‘This patient took this medicine at that time.’”

Blockchain can be implemented to bring multiple states and companies into a single system and thus help avoid situations where patients travel abroad to get new prescriptions.

We reported last month the rather interesting news that Intel had filed a patent application for a Bitcoin mining product that can cut electricity consumption.


This article appeared first on Cryptovest

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.